About Meves Pharmaceuticals

About company

Meves Pharmaceuticals is developing nucleoside based therapies for mitochondrial DNA (mtDNA) depletion syndromes (MDS or MDDS), a category of severe genetic diseases. The initial focus is on therapy tailored specifically to treat patients with Thymidine Kinase 2 (TK2) deficiency, a discrete monogenic disorder associated with profound skeletal myopathy.